Kirkland Advises HarbourVest on Lead Investment in $1.1 Billion Continuation Vehicle for Azurity Pharmaceuticals

Kirkland & Ellis advised HarbourVest Partners, LLC as the lead investor in QHP Capital L.P.’s $1.1 billion single-asset continuation vehicle for Azurity Pharmaceuticals, Inc. The transaction provides liquidity to existing limited partners while enabling QHP to maintain control and continue executing on Azurity’s long-term value creation plan.

Read the transaction press release

The Kirkland team included investment funds lawyers Tarsis Goncalves, Joseph Salvatore, Brandon Barrett and Sam Bialczak; tax lawyer Elie Zolty; and antitrust & competition lawyer Rebekah Tobison Scherr.